• Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022
• The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications
• Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral nicotine delivery

Diabetes, rheumatoid disease, Alzheimer’s Disease, and estrogen delivery, are some of the multiple indications that drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) is planning to target with its research and development programs next year. The markets targeted provide multiple opportunities for success and are now expected to reach an overall estimated value of more than $160 billion annually, worldwide over the next few years. 

The company will conduct pharmacokinetic and efficacy modelling studies to determine if its patented DehydraTECH(TM) technology can be used successfully to improve delivery of drugs or active pharmaceutical ingredients in these sectors, and to determine if there are specific commercial benefits to continue pursuing these markets.

The largest sector targeted by the company is currently the diabetes therapeutics market, expected to reach $77.9 billion worldwide by 2024 (https://ibn.fm/PAFA0). With diabetes being the seventh largest cause of death in the United States, the market has the potential to generate impressive growth opportunities for the company. Lexaria’s R&D program for this indication, titled DIAB-A22-1 and likely to be launched in November 2022, will explore the impact of cannabidiol (“CBD”) delivered through the company’s proprietary DehydraTECH technology. 

Another major target market the company is the rheumatoid arthritis therapeutics sector, expected to reach a value of over $30 billion per year by 2025 (https://ibn.fm/pYzqd). There are currently over 100 rheumatic diseases, including rheumatoid arthritis, osteoarthritis, and fibromyalgia. The company’s RHEUM-A22-1 efficacy study, likely to be launched in October 2022, will look into how DehydraTECH-CBD can potentially affect the treatment of rheumatoid arthritis, given CBD’s efficacy to reduce inflammation.

The program DEM-A22-1, likely to begin in July 2022, will assess the use of DehydraTECH-delivered CBD, both paired with nicotine and without it, for the potential treatment of dementia. The dementia therapeutics market is estimated to reach $19.6 billion by 2026 and there are currently about 55 million people affected by dementia worldwide, with approximately 78 million more expected to face some form of dementia by 2030 (https://ibn.fm/aQpsi). The most common form of dementia is Alzheimer’s disease, accounting for roughly 60 percent of all cases.

Another program targeting a major market is HOR-A22-1, a pharmacokinetic study that will try to determine if DehydraTECH can be used to enhance and improve the delivery characteristics of estrogen. Amid growing awareness of post-menopausal issues women face, and an increase in the prevalence of menopausal disorder, the hormone replacement market is anticipated to grow exponentially and reach $46.5 billion by 2027 (https://ibn.fm/8trBY). Lexaria Bioscience’s estrogen delivery study is tentatively scheduled to being in April 2022.

In addition to the new R&D programs, Lexaria will continue the programs launched previously to explore the potential impact of DehydraTECH-delivered CBD on hypertension and heart disease, as well as the technology’s use for oral nicotine delivery as a potential alternative to smoking. Heart disease and smoking are the first and third, respectively, causes of death in the United States.

With all the programs for 2022 fully funded due to the $15 million raised by the company this year, Lexaria is going into the new year with a busy roster of R&D programs.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.